The Federal Trade Commission has reached a settlement with Surescripts that would prohibit the prescription-technology company from engaging in exclusionary conduct and enforcing noncompete agreements.
The FTC on Thursday proposed an order in federal district court that would resolve the agency’s claim that Surescripts used anticompetitive tactics in an unlawful effort to monopolize the e-prescription drug market illegally.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]